Charles River Laboratories International (CRL) EBITDA (2009 - 2026)

Charles River Laboratories International has reported EBITDA for 18 years, with the latest figure at $119.9 million in Q2 2026.

• On a quarterly basis, EBITDA rose 19.73% year-over-year to $119.9 million in Q2 2026; TTM through Jun 2026 was $90.1 million, a 27.61% decrease from a year earlier, with the FY2025 full-year figure at $25.2 million, down 88.93% from the prior year.
• EBITDA was $119.9 million for Q2 2026 at Charles River Laboratories International, roughly flat from $119.9 million in the prior quarter.
• The five-year high for EBITDA was $187.4 million in Q2 2022, with the low at -$283.4 million in Q4 2025.
• Average EBITDA over 5 years is $97.8 million, with a median of $133.4 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: EBITDA slumped 226.15% in 2024, then jumped 60.57% in 2026.
• Over 5 years, EBITDA stood at $163.8 million in 2022, then decreased by 18.86% to $132.9 million in 2023, then plunged by 226.15% to -$167.7 million in 2024, then slumped by 69.03% to -$283.4 million in 2025, then jumped by 142.3% to $119.9 million in 2026.
• The last three EBITDA figures came in at $119.9 million (Q2 2026), $119.9 million (Q1 2026), and -$283.4 million (Q4 2025), per Business Quant data.